C1orf115 Inhibitors
C1orf115 inhibitors encompass a diverse array of chemicals that serve to impede the functional activity of this protein through various biochemical pathways. These inhibitors work by targeting the intricate network of signaling pathways C1orf115 is involved in, rather than by suppressing its gene expression or protein translation. For instance, certain inhibitors disrupt cell cycle progression, which is critical if C1orf115 is implicated in regulating cell cycle checkpoints. Such cell cycle inhibitors induce a phase arrest that would hinder the progression to stages where C1orf115 might be active. Other inhibitors directly target key signaling cascades like the PI3K/AKT/mTOR pathway, which, when obstructed, would lead to downstream diminishment of C1orf115 activity. This would be particularly impactful if C1orf115's function were contingent upon the signals propagated through this pathway. Moreover, specific inhibitors that interfere with protein neddylation processes could diminish C1orf115 activity by averting the post-translational modifications necessary for its stability or interaction with other cellular components.
The inhibition mechanisms further extend to molecular pathways that involve stress responses, growth factor signaling, and WNT/β-catenin homeostasis. By blocking these pathways, inhibitors indirectly reduce the functional activity of C1orf115. For example, compounds that inhibit stress-responsive kinases or the mTORC1 complex would be expected to decrease C1orf115 activity if it is part of the cellular response to environmental stress or if it is regulated by growth conditions. Tankyrase inhibitors, which influence WNT/β-catenin signaling, are another example where the diminution of C1orf115 could occur through the stabilization of β-catenin levels, affecting the pathway that might regulate C1orf115 indirectly. Collectively, these inhibitors function by attenuating signaling events or protein interactions essential for the proper functioning of C1orf115, thereby establishing a comprehensive inhibitory profile that spans multiple cellular processes and signaling pathways.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
A CDK4/6 inhibitor that can disrupt cell cycle progression. If C1orf115 is involved in cell cycle regulation, PD 0332991-induced G1 phase arrest would consequently diminish C1orf115 activity by preventing the cell cycle from reaching stages where C1orf115 is active. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor that impedes the PI3K/AKT/mTOR pathway. If C1orf115 function is linked to this pathway, suppression of PI3K activity would result in a downstream decrease in C1orf115 activity by reducing the pathway's overall signaling, which could be necessary for C1orf115's functional activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A p38 MAPK inhibitor that can inhibit the p38 MAPK pathway. If C1orf115 is modulated by stress responses mediated by p38 MAPK, then SB203580 would diminish the functional activity of C1orf115 by blocking the pathway's signaling events that are necessary for C1orf115 activation or expression. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor that can suppress the mTORC1 pathway. If C1orf115 is part of growth factor signaling involving mTOR, rapamycin would lead to a reduction in C1orf115 activity by inhibiting the mTORC1 complex, which may be upstream or parallel to C1orf115 signaling, affecting its activity or stability. | ||||||
ATM/ATR Kinase Inhibitor Inhibitor | 905973-89-9 | sc-202964 | 5 mg | $106.00 | 8 | |
A NEDD8-activating enzyme inhibitor which affects protein neddylation. If C1orf115 requires neddylation for its activity or stability, ATM/ATR Kinase Inhibitor would lead to a decrease in C1orf115 activity by preventing its neddylation, which could be critical for its functional conformation or interaction with other proteins. | ||||||
XAV939 | 284028-89-3 | sc-296704 sc-296704A sc-296704B | 1 mg 5 mg 50 mg | $36.00 $117.00 $525.00 | 26 | |
A tankyrase inhibitor affecting WNT/β-catenin signaling. If C1orf115 is part of the WNT/β-catenin pathway indirectly, XAV-939 would lead to decreased activity of C1orf115 by inhibiting tankyrase, which is necessary for the homeostasis of β-catenin levels that could regulate C1orf115 activity. | ||||||
Dorsomorphin dihydrochloride | 1219168-18-9 | sc-361173 sc-361173A | 10 mg 50 mg | $186.00 $751.00 | 28 | |
An inhibitor of BMP signaling which targets AMPK, ALK2, ALK3, and ALK6. If C1orf115 is involved in TGF-β/BMP pathway-mediated processes, dorsomorphin would diminish C1orf115 activity by blocking this signaling pathway, which might be upstream of C1orf115 and necessary for its full activation. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
A proteasome inhibitor that could affect protein turnover. If C1orf115 activity is regulated through proteasomal degradation, bortezomib could lead to an indirect decrease in C1orf115 activity by stabilizing negative regulators of C1orf115 or by accumulating ubiquitinated proteins that sequester C1orf115. | ||||||